Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of adiponectin genetic polymorphism on rosiglitazone response

Trial Profile

Effect of adiponectin genetic polymorphism on rosiglitazone response

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Oct 2009 Last checked against ClinicalTrials.gov record.
    • 13 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top